Primary Site >> Pancreatic Cancer
Gene >> UGT1A1
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
Ref: UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. PMID: 12806614 |
Ref: Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients. PMID: 17072959 |
Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: Networking of differentially expressed genes in human cancer cells resistant to methotrexate. PMID: 19732436 |
Ref: The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. PMID: 20127092 |
Ref: Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. PMID: 23053265 |
Ref: Pharmacogenetics in pancreatic cancer. PMID: 25076337 |
Ref: Increased UGT1A3 and UGT1A7 expression is associated with pancreatic cancer. PMID: 25743847 Ref: Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. PMID: 26631878 |
Ref: [A Case of Unresectable Advanced Rectal Cancer with a Pancreatic Tumor That Was Successfully Treated with FOLFIRINOX]. PMID: 28133357 |
Ref: Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. PMID: 28804517 Ref: Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. PMID: 28837958 |
Ref: Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. PMID: 29932028 |